{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:24:40Z","timestamp":1792448680788,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ard.2025.11.015","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T22:28:26Z","timestamp":1764973706000},"page":"476-488","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment"],"prefix":"10.1016","volume":"85","author":[{"given":"Nancy","family":"Agmon-Levin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislav","family":"Ignatenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Gordienko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefina","family":"Cort\u00e9s-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pongthorn","family":"Narongroeknawin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Romanowska-Pr\u00f3chnicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Cifersk\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanari","family":"Kodera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei J","family":"Cheng-Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Leszczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joung-Liang","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Mysler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafal","family":"Wojciechowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tunde","family":"Tarr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Vishneva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hsing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Finzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberta","family":"Hoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajchara","family":"Koolvisoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Lie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"Rojkovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugeny","family":"Zotkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Francoise","family":"Viallard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berta Paula Magallares","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati Aashish","family":"Ghanshani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Avrameas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Sips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen John","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ard.2025.11.015_bib0001","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMra071297","article-title":"Systemic lupus erythematosus","volume":"358","author":"Rahman","year":"2008","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ard.2025.11.015_bib0002","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1136\/annrheumdis-2013-205171","article-title":"Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort","volume":"74","author":"Bruce","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.11.015_bib0003","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1177\/0961203318817132","article-title":"Disease course patterns in systemic lupus erythematosus","volume":"28","author":"Tselios","year":"2019","journal-title":"Lupus"},{"issue":"6","key":"10.1016\/j.ard.2025.11.015_bib0004","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.ard.2025.11.015_bib0005","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1136\/ard-2023-225319","article-title":"Management of systemic lupus erythematosus: a systematic literature review informing the 2023 update of the EULAR recommendations","volume":"83","author":"Kostopoulou","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.ard.2025.11.015_bib0006","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"9767","key":"10.1016\/j.ard.2025.11.015_bib0007","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ard.2025.11.015_bib0008","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.ard.2025.11.015_bib0009","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2025.11.015_bib0010","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ard.2025.11.015_bib0011","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1002\/art.10541","article-title":"An open study of B lymphocyte depletion in systemic lupus erythematosus","volume":"46","author":"Leandro","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ard.2025.11.015_bib0012","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.ard.2025.11.015_bib0013","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ard.2025.11.015_bib0014","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"15","key":"10.1016\/j.ard.2025.11.015_bib0015","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","article-title":"Efficacy and safety of obinutuzumab in active lupus nephritis","volume":"392","author":"Furie","year":"2025","journal-title":"N Engl J Med"},{"issue":"30","key":"10.1016\/j.ard.2025.11.015_bib0016","doi-asserted-by":"crossref","first-page":"26733","DOI":"10.1074\/jbc.M202069200","article-title":"Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fc\u03b3RIII and antibody-dependent cellular toxicity","volume":"277","author":"Shields","year":"2002","journal-title":"J Biol Chem"},{"issue":"10320","key":"10.1016\/j.ard.2025.11.015_bib0017","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren\u2019s syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ard.2025.11.015_bib0018","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2018-214720","article-title":"Treatment of primary Sj\u00f6gren\u2019s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity","volume":"78","author":"D\u00f6rner","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.ard.2025.11.015_bib0019","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/ard.2007.079418","article-title":"B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response","volume":"67","author":"Cambridge","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.ard.2025.11.015_bib0020","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.ard.2025.11.015_bib0021","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","article-title":"The 1982 revised criteria for the classification of systemic lupus erythematosus","volume":"25","author":"Tan","year":"1982","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.ard.2025.11.015_bib0022","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.ard.2025.11.015_bib0023","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/rheumatology\/keh624","article-title":"Development and initial validation of an updated version of the British Isles Lupus Assessment Group\u2019s disease activity index for patients with systemic lupus erythematosus","volume":"44","author":"Isenberg","year":"2005","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.ard.2025.11.015_bib0024","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1136\/ard.2010.132068","article-title":"An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA","volume":"70","author":"Isenberg","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.ard.2025.11.015_bib0025","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1093\/rheumatology\/keq026","article-title":"Numerical scoring for the BILAG-2004 index","volume":"49","author":"Yee","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.ard.2025.11.015_bib0026","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1002\/art.22162","article-title":"Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity","volume":"54","author":"Yee","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.ard.2025.11.015_bib0027","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/art.24698","article-title":"Novel evidence-based systemic lupus erythematosus responder index","volume":"61","author":"Furie","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.ard.2025.11.015_bib0028","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.ard.2025.11.015_bib0029","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.11.015_bib0030","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"issue":"11","key":"10.1016\/j.ard.2025.11.015_bib0031","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/keg382","article-title":"Definition and treatment of lupus flares measured by the BILAG index","volume":"42","author":"Gordon","year":"2003","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.ard.2025.11.015_bib0032","first-page":"811","article-title":"Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis","volume":"32","author":"Cella","year":"2005","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.ard.2025.11.015_bib0033","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0885-3924(96)00274-6","article-title":"Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system","volume":"13","author":"Yellen","year":"1997","journal-title":"J Pain Symptom Manage"},{"issue":"11","key":"10.1016\/j.ard.2025.11.015_bib0034","doi-asserted-by":"crossref","first-page":"e751","DOI":"10.1016\/S2665-9913(24)00162-0","article-title":"Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials","volume":"6","author":"Parodis","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"5","key":"10.1016\/j.ard.2025.11.015_bib0035","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/ard-2022-222748","article-title":"Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus","volume":"82","author":"Morand","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.ard.2025.11.015_bib0036","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.20430","article-title":"B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab","volume":"50","author":"Looney","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.ard.2025.11.015_bib0037","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/art.30152","article-title":"Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion","volume":"63","author":"Vital","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.ard.2025.11.015_bib0038","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1093\/rheumatology\/keab827","article-title":"Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab?","volume":"61","author":"Reddy","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.ard.2025.11.015_bib0039","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.autrev.2010.07.006","article-title":"Predictive factors of response to rituximab therapy in rheumatoid arthritis: what do we know today?","volume":"9","author":"Benucci","year":"2010","journal-title":"Autoimmun Rev"},{"issue":"10","key":"10.1016\/j.ard.2025.11.015_bib0040","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/art.38074","article-title":"Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus","volume":"65","author":"Carter","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.ard.2025.11.015_bib0041","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1136\/ard-2024-225686","article-title":"Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study","volume":"83","author":"Aranow","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.11.015_bib0042","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/art.41466","article-title":"Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis","volume":"73","author":"Atisha-Fregoso","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.ard.2025.11.015_bib0043","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.7326\/M21-2078","article-title":"Effectiveness of belimumab after rituximab in systemic lupus erythematosus: a randomized controlled trial","volume":"174","author":"Shipa","year":"2021","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.ard.2025.11.015_bib0044","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1093\/rheumatology\/kez623","article-title":"A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE","volume":"59","author":"van Dam","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.ard.2025.11.015_bib0045","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1093\/ndt\/gfaa117","article-title":"Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results","volume":"36","author":"Kraaij","year":"2021","journal-title":"Nephrol Dial Transplant"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725045479?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725045479?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T12:26:00Z","timestamp":1786191960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725045479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0003496725045479"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.11.015","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}